← Back to Search

Surveillance arm for Multiple Trauma (SToP Trial)

N/A
Waitlist Available
Led By Sarah Majercik, MD,MBA
Research Sponsored by Intermountain Health Care, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

SToP Trial Summary

This is a prospective, randomized vanguard trial of trauma patients admitted to the trauma surgery service at Intermountain Medical Center who are deemed to be at high risk for venous thromboembolism. Once identified and enrolled, subjects will be randomized to receive bilateral lower extremity duplex ultrasound surveillance versus no surveillance. The study will compare the two groups with regard to deep vein thrombosis, pulmonary embolism, and major and clinically relevant bleeding episode rates, both during the index hospitalization and at 90 days post-discharge.

Eligible Conditions
  • Multiple Trauma
  • Deep Vein Thrombosis

SToP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Asymptomatic lower extremity DVT
Secondary outcome measures
All cause mortality
Composite outcome of proximal DVT plus major and clinically relevant bleeding episodes
Major and clinically relevant bleeding episodes
+3 more

SToP Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Surveillance armExperimental Treatment1 Intervention
Bilateral duplex ultrasound surveillance
Group II: No surveillance armActive Control1 Intervention
no duplex ultrasound surveillance

Find a Location

Who is running the clinical trial?

Intermountain Health Care, Inc.Lead Sponsor
137 Previous Clinical Trials
1,961,110 Total Patients Enrolled
Sarah Majercik, MD,MBAPrincipal InvestigatorIntermountain Health Care, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~247 spots leftby May 2025